Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,706 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vision Therapy Clear all
Recruiting Phase 2 Interventional

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
347
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 265 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 5:08 PM EDT
Completed Phase 1 Interventional

Haploidentical Stem Cell Transplant for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Ultrasound

NCT00152113
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Hematopoietic Stem Cell Transplantation, CliniMACS, See intervention description
Procedure · Device · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 16 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 28, 2026, 5:08 PM EDT
Completed Not applicable Interventional Results available

The Safety and Effectiveness of UroLift: LIFT Pivotal Study

NCT01294150
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift System, Cystoscopy, Crossover
Device · Other
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
San Diego, California • San Jose, California • Englewood, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 28, 2026, 5:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Breathe Easier II: A Dyad-based Multiple Behavior Intervention

NCT05956782
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, COPD, Self-Management, Physical Inactivity, Stress, Quality of Life
Interventions
Breathe Easier
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 28, 2026, 5:08 PM EDT
Completed Not applicable Interventional Results available

REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation

NCT01858194
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Renal sympathetic denervation, VT ablation alone
Device
Lead sponsor
Vivek Reddy
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 28, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis

NCT03286556
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Acute Fatal Form
Interventions
Autoantibody Reductive Therapy, Treatment as Usual (TAU)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 85 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Chicago, Illinois • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 28, 2026, 5:08 PM EDT
Completed Phase 3 Interventional Results available

Anti-VEGF Treatment for Prevention of PDR/DME

NCT02634333
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Prompt Sham, Prompt aflibercept, Deferred laser, Deferred aflibercept
Procedure · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
81
States / cities
Phoenix, Arizona • Tucson, Arizona • Huntington Beach, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 28, 2026, 5:08 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Testing Effectiveness of a Stochastic Noise Stimulator to Immediately Improve Balance and Gait

NCT06688578
View directory record Official record
Conditions
Vestibular Disorder, Aging
Interventions
Subperceptual Stimulus, Sham Comparator
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 28, 2026, 5:08 PM EDT
Completed Phase 4 Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

NCT05626478
View directory record Official record
Conditions
Corneal Edema, Corneal Defect, Anterior Chamber Inflammation, Ocular Pain, Corneal Staining, Visual Outcome, CME - Cystoid Macular Edema
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 28, 2026, 5:08 PM EDT
Completed Phase 2 Interventional

Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00005592
View directory record Official record
Conditions
Lymphoma
Interventions
90-Y-ibritumomab tiuxetan, rituximab, indium In 111 ibritumomab tiuxetan
Biological · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 28, 2026, 5:08 PM EDT
Completed Not applicable Interventional

Project Motion, A Study of Motivational Interviewing to Reduce Heavy or Problematic Drinking

NCT00665249
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Abuse
Interventions
Motivational Interviewing, Spirit-Only Motivational Interviewing, Self-Change
Behavioral · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 28, 2026, 5:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Manual Medicine or Cognitive Behavioral Therapy With Chronic Uncontrolled Diabetes

NCT02971865
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CBT/CMT, Control group traditional primary care
Behavioral · Other
Lead sponsor
Community Wellness Center, West Linn, OR
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
West Linn, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 28, 2026, 5:08 PM EDT
Terminated Phase 2 Interventional Results available

Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

NCT05263505
View directory record Official record
Conditions
Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis
Interventions
Baricitinib 2 MG [Olumiant], Methotrexate, Azathioprine, Mycophenolate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 28, 2026, 5:08 PM EDT
Completed Phase 3 Interventional Results available

Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)

NCT00117572
View directory record Official record
Conditions
Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Nasal Cavity, Paranasal Sinus Neoplasms, Cancer of the Oral Cavity
Interventions
docetaxel, cisplatin, hydroxyurea, fluorouracil, chemotherapy, radiotherapy
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
20
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 28, 2026, 5:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Accommodation Behavior in Children Under Myopia Control Treatment (Pilot Study)

NCT04807361
View directory record Official record
Conditions
Accomodation, Biofeedback Training, Myopia
Interventions
Auditory biofeedback traing
Behavioral
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
8 Years to 15 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Long Beach, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 28, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

NCT01946529
View directory record Official record
Conditions
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Interventions
vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, temozolomide, temsirolimus, bevacizumab, sorafenib, surgery, radiation
Drug · Procedure · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 28, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

NCT00061893
View directory record Official record
Conditions
Sarcoma
Interventions
celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, conventional surgery, radiation therapy, MESNA, Filgrastim
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 28, 2026, 5:08 PM EDT
Recruiting No phase listed Observational

A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae

NCT06006884
View directory record Official record
Conditions
COVID-19
Interventions
Bronchoscopies and Bronchoalveolar Lavages (BALs), Chest Tomography (CT), Electrocardiogram (ECG), Pulmonary function tests (PFTs), 6 minute walk test (6MWT)
Procedure · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 28, 2026, 5:08 PM EDT
Recruiting Phase 4 Interventional

Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension

NCT07588152
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Netarsudil Ophthalmic Solution (Rhopressa), Artificial Tears (AT)
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 28, 2026, 5:08 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

NCT03587116
View directory record Official record
Conditions
Hemophilia B, Hemophilia A
Interventions
Standard of Care FIX Replacement therapy, Standard of Care FVIII Replacement therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
13
States / cities
Palo Alto, California • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 28, 2026, 5:08 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Simulines Non-Inferiority Pivotal Study

NCT02736825
View directory record Official record
Conditions
Skin Laxity
Interventions
Ulthera System with standard transducer, Ulthera System with prototype 2 simulines transducer
Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
30 Years to 70 Years
Enrollment
262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
8
States / cities
Beverly Hills, California • Roseville, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 28, 2026, 5:08 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

NCT04499248
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
42
States / cities
Sun City, Arizona • Glendale, California • Inglewood, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 28, 2026, 5:08 PM EDT
Recruiting Not applicable Interventional

Developing Evidence-Based Cognitive Approaches to Improve Adjustment to Vision Loss

NCT07073521
View directory record Official record
Conditions
Depression, Anxiety, Visual Impairment, Adjustment, Adjustment Disorder With Anxious Mood, Adjustment Disorder With Depressed Mood, Blindness, Acquired, Blindness and Low Vision, Vision Loss
Interventions
Integrated Cognitive Behavioral Therapy (CBT) & Mindfulness Group Intervention for Adjustment to Vision Loss
Behavioral
Lead sponsor
The Chicago Lighthouse
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 28, 2026, 5:08 PM EDT
Completed Not applicable Interventional

Targeted Evaluation, Action, & Monitoring of Traumatic Brain Injury

NCT02657135
View directory record Official record
Conditions
Traumatic Brain Injury (TBI)
Interventions
Cognitive/Neuropsychological Testing, Vestibular/Ocular-Motor Testing, Cervical (Neck) Evaluation, Sleep Evaluation, HDFT MRI, MR Spectroscopy (MRS), MEG (Magnetoencephalography)
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 28, 2026, 5:08 PM EDT